首页> 美国卫生研究院文献>Chemical Science >Degradable polymer prodrugs with adjustable activity from drug-initiated radical ring-opening copolymerization
【2h】

Degradable polymer prodrugs with adjustable activity from drug-initiated radical ring-opening copolymerization

机译:通过药物引发的自由基开环共聚反应可调节活性的可降解聚合物前药

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Degradable polymer prodrugs based on gemcitabine (Gem) as an anticancer drug were synthesized by ‘drug-initiated’ nitroxide-mediated radical ring-opening copolymerization (NMrROP) of methacrylic esters and 2-methylene-4-phenyl-1,3-dioxolane (MPDL). Different structural parameters were varied to determine the best biological performances: the nature of the monomer [i.e., oligo(ethylene glycol) methacrylate (OEGMA) or methyl methacrylate (MMA)], the nature of the Gem-polymer linker (i.e., amide or amide and diglycolate) and the MPDL content in the copolymer. Depending on the nature of the methacrylate monomer, two small libraries of water-soluble copolymer prodrugs and nanoparticles were obtained (Mn ∼10 000 g mol–1, Đ = 1.1–1.5), which exhibited tunable hydrolytic degradation under accelerated conditions governed by the MPDL content. Drug-release profiles in human serum and in vitro anticancer activity on different cell lines enabled preliminary structure–activity relationships to be established. The cytotoxicity was independently governed by: (i) the MPDL content – the lower the MPDL content, the greater the cytotoxicity; (ii) the nature of the linker – the presence of a labile diglycolate linker enabled a greater Gem release compared to a simple amide bond and (iii) the hydrophilicity of the methacrylate monomer–OEGMA enabled a greater anticancer activity to be obtained compared to MMA-based polymer prodrugs. Remarkably, the optimal structural parameters enabled reaching the cytotoxic activity of the parent (free) drug.
机译:以吉西他滨(Gem)为抗癌药,通过甲基丙烯酸酯与2-亚甲基-4-苯基-1,3-二氧戊环的“药物引发”硝基氧介导的自由基开环共聚(NMrROP)合成了可降解的聚合物前药。 MPDL)。改变不同的结构参数以确定最佳的生物学性能:单体的性质[即低聚(乙二醇)甲基丙烯酸甲酯(OEGMA)或甲基丙烯酸甲酯(MMA)],宝石-聚合物接头的性质(即酰胺或酰胺和二甘醇酸酯)和共聚物中的MPDL含量。根据甲基丙烯酸酯单体的性质,获得了两个小的水溶性共聚物前药和纳米颗粒库(Mn〜10 000 g mol -1 ,Đ= 1.1-1.5),具有可调节的水解性。在MPDL含量决定的加速条件下性能下降。人血清中的药物释放曲线以及在不同细胞系上的体外抗癌活性使得能够建立初步的结构-活性关系。细胞毒性由以下因素独立控制:(i)MPDL含量– MPDL含量越低,细胞毒性越大; (ii)接头的性质–与简单的酰胺键相比,不稳定的二甘醇酸酯接头的存在使Gem释放更大,并且(iii)甲基丙烯酸酯单体– OEGMA的亲水性与MMA相比,具有更大的抗癌活性基聚合物前药。值得注意的是,最佳的结构参数能够达到母体(游离)药物的细胞毒活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号